Literature DB >> 17765526

Global burden of COPD: risk factors, prevalence, and future trends.

David M Mannino1, A Sonia Buist.   

Abstract

Chronic obstructive pulmonary disease (COPD) continues to be an important cause of morbidity, mortality, and health-care costs worldwide. It is a global health issue, with cigarette smoking being an important risk factor universally; other factors, such as exposure to indoor and outdoor air pollution, occupational hazards, and infections, are also important. As the global population ages, the burden of COPD will increase in years to come. Prevalence estimates of the disorder show considerable variability across populations, suggesting that risk factors can affect populations differently. Other advances in our understanding of COPD are increased recognition of the importance of comorbid disease, identification of different COPD phenotypes, and understanding how factors other than lung function affect outcome in our patients. The challenge we will all face in the next few years will be implementation of cost-effective prevention and management strategies to stem the tide of this disease and its cost.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17765526     DOI: 10.1016/S0140-6736(07)61380-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  645 in total

1.  CX3CR1+ lung mononuclear phagocytes spatially confined to the interstitium produce TNF-α and IL-6 and promote cigarette smoke-induced emphysema.

Authors:  Zeyu Xiong; Adriana S Leme; Prabir Ray; Steven D Shapiro; Janet S Lee
Journal:  J Immunol       Date:  2011-01-28       Impact factor: 5.422

2.  In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model.

Authors:  Yu-Feng Zhou; Meng-Ting Tao; Wei Huo; Xiao-Ping Liao; Jian Sun; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study.

Authors:  Tuula Toljamo; Marjo Kaukonen; Pentti Nieminen; Vuokko L Kinnula
Journal:  Scand J Prim Health Care       Date:  2010-03       Impact factor: 2.581

4.  A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease.

Authors:  Francesca Polverino; Maria E Laucho-Contreras; Hans Petersen; Vanesa Bijol; Lynette M Sholl; Mary E Choi; Miguel Divo; Victor Pinto-Plata; Alfredo Chetta; Yohannes Tesfaigzi; Bartolomé R Celli; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

5.  Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults.

Authors:  Sandy S Chang; Shu Chen; Gail J McAvay; Mary E Tinetti
Journal:  J Am Geriatr Soc       Date:  2012-10-04       Impact factor: 5.562

6.  Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery.

Authors:  Takashi Makino; Hajime Otsuka; Yoshinobu Hata; Satoshi Koezuka; Yoko Azuma; Kazutoshi Isobe; Keishi Sugino; Satoru Ebihara; Sakae Homma; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2018-03-26

Review 7.  Exposure to nitrogen dioxide and chronic obstructive pulmonary disease (COPD) in adults: a systematic review and meta-analysis.

Authors:  Zili Zhang; Jian Wang; Wenju Lu
Journal:  Environ Sci Pollut Res Int       Date:  2018-03-20       Impact factor: 4.223

8.  The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; Ruth Navarro-Artieda; Jordi Ibáñez-Nolla
Journal:  Lung       Date:  2014-05-10       Impact factor: 2.584

9.  Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.

Authors:  Yosuke Yamada; Utano Tomaru; Akihiro Ishizu; Tomoki Ito; Takayuki Kiuchi; Ayako Ono; Syota Miyajima; Katsura Nagai; Tsunehito Higashi; Yoshihiro Matsuno; Hirotoshi Dosaka-Akita; Masaharu Nishimura; Soichi Miwa; Masanori Kasahara
Journal:  Lab Invest       Date:  2015-04-27       Impact factor: 5.662

10.  Patients' perspective of the impact of COPD on quality of life: a focus group study for patients with COPD.

Authors:  Anan Jarab; Eman Alefishat; Tareq Mukattash; Karem Alzoubi; Sharrel Pinto
Journal:  Int J Clin Pharm       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.